Tag: Oberland Capital

Company News: Oberland Capital Raises $425 Million Healthcare Royalty and Credit Opportunities Fund


– Significantly Exceeds Target –

Oberland Capital, an investment firm focused on the global healthcare industry, announced today the closing of its inaugural royalty and credit opportunities fund, Oberland Capital Healthcare, with $425 million in capital commitments.

Oberland Capital provides healthcare companies, institutions and inventors customized financing solutions with an emphasis on the biopharmaceutical, medical device and diagnostic sectors.  The fund targets investments ranging from $15 million to $100 million and has the ability to execute substantially larger transactions.

“We are grateful for the support shown by our limited partners in helping us to significantly surpass the $350 million target size for our first fund.  The strong response from investors is a testament to the quality and experience of our investment team and the demand for non-correlated investment strategies.  We look forward to building a diversified portfolio of attractive healthcare investments,” said Andrew Rubinstein, Managing Partner.

The development and commercialization of breakthrough medical technologies is highly capital intensive, creating a large market opportunity for Oberland Capital Healthcare.  “Our flexible, long-term financing solutions provide an attractive source of capital to healthcare companies, institutions and inventors,” added Jean-Pierre Naegeli, Managing Partner.  “We are excited to work with our transaction partners worldwide to enable them to meet their strategic and financial objectives.”

Investors in Oberland Capital Healthcare include public and corporate pension plans, financial institutions, foundations and endowments located throughout the United States and Europe.

Company News: Peter Zerhouni new CEO of InDex Pharmaceuticals

InDex Pharmaceuticals today announced that the Board of Directors has named Peter Zerhouni as new CEO. Peter Zerhouni comes from a position as CEO at Diamyd Medical AB where he has been instrumental in bringing the company’s business and clinical trials forward. He will succeed Jesper Wiklund, who has led the company since 2011.

Peter Zerhouni has a combined financial and biotechnology background with both biology and MBA degrees from the University of Lund in Sweden and the University of California, Berkeley, USA. Peter is since 2011 CEO of the publicly listed life science company Diamyd Medical AB where he also has been head of Business Development. He was a driving force behind one of the largest biotech out-licensing deals in Sweden in 2010. Peter has previously held various positions at ING Bank in Brussels and Amsterdam.

InDex Pharmaceuticals’ current CEO, Jesper Wiklund, has decided to leave the company to take on a position as Managing Director Europe at Oberland Capital, a life science focused investment firm based in the United States.

Peter Zerhouni takes over as CEO from April 1st, 2015.